Berger Financial Group, Inc Incyte Corp Transaction History

Berger Financial Group, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$52.16 - $64.19 $11,057 - $13,608	212 Added 0.35%	60,468 $3.8 Million
Q3 2023 Nov 03, 2023	BUY	$57.77 - $65.93 $110,571 - $126,190	1,914 Added 3.28%	60,256 $3.48 Million
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $38,947 - $48,250	-639 Reduced 1.08%	58,342 $3.63 Million
Q1 2023 Apr 24, 2023	BUY	$70.23 - $86.01 $4.14 Million - $5.07 Million	58,981 New	58,981 $4.26 Million
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $3.22 Million - $3.89 Million	-48,774 Closed	0 $0
Q4 2021 Jan 26, 2022	BUY	$63.34 - $74.11 $217,572 - $254,567	3,435 Added 7.58%	48,774 $3.58 Million
Q3 2021 Oct 28, 2021	BUY	$68.67 - $84.02 $73,202 - $89,565	1,066 Added 2.41%	45,339 $3.12 Million
Q2 2021 Jul 29, 2021	BUY	$79.87 - $87.53 $239,210 - $262,152	2,995 Added 7.26%	44,273 $3.73 Million
Q1 2021 May 12, 2021	BUY	$76.02 - $100.5 $3.14 Million - $4.15 Million	41,278 New	41,278 $3.36 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Berger Financial Group, Inc, based on Form 13F filings with the SEC.

Stay updated on Berger Financial Group, Inc with notifications on news.